Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best dividend stocks on Robinhood. The start of 2020 marked a turning point for retail ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best cancer stocks to buy. Cancer is the second leading cause of death across the globe ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda. Now, it seems a key part of that effort will come ...

Merck & Co has said building its cardiovascular medicines business is central to its strategy to manage the loss of patent protection of cancer juggernaut Keytruda in five years, and new studies ...